AMGEN INC — Director's Dealing 2025

Feb 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-02-19

Reporting Person: REESE DAVID M (EVP & Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-19	Common Stock	M	8711	$156.35	Acquired	70858	Direct
2025-02-19	Common Stock	S	8711	$293.2182	Disposed	62147	Direct
2025-02-21	Common Stock	S	25225	$304.441	Disposed	36922	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-19	Nqso (Right to Buy)	$156.35	M	8711	Disposed	2026-05-03	Common Stock (8711)	Direct

Footnotes

F1: These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.

F2: The price reported is an average price. The prices ranged from $291.90 to $295.97 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F3: The price reported is an average price. The prices ranged from $297.19 to $305.33 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F4: These shares include 707 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.